CymaBay Therapeutics (NASDAQ:CBAY) Reaches New 52-Week High at $25.72

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAYGet Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.72 and last traded at $24.89, with a volume of 549844 shares traded. The stock had previously closed at $24.00.

Analyst Ratings Changes

CBAY has been the subject of a number of research reports. Piper Sandler upped their price objective on shares of CymaBay Therapeutics from $19.00 to $33.00 and gave the stock an “overweight” rating in a research note on Monday, November 6th. Raymond James raised their price objective on CymaBay Therapeutics from $33.00 to $34.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. William Blair reissued an “outperform” rating on shares of CymaBay Therapeutics in a research report on Tuesday, November 14th. Lifesci Capital restated an “outperform” rating on shares of CymaBay Therapeutics in a research note on Tuesday, December 26th. Finally, HC Wainwright upped their price target on CymaBay Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, December 15th. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.70.

Check Out Our Latest Research Report on CymaBay Therapeutics

CymaBay Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.32, a current ratio of 22.76 and a quick ratio of 22.76. The company’s fifty day moving average is $23.11 and its two-hundred day moving average is $17.74.

CymaBay Therapeutics (NASDAQ:CBAYGet Free Report) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). During the same period in the previous year, the business posted ($0.28) EPS. On average, analysts forecast that CymaBay Therapeutics, Inc. will post -0.95 earnings per share for the current year.

Insider Transactions at CymaBay Therapeutics

In related news, insider Charles Mcwherter sold 11,342 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $18.28, for a total value of $207,331.76. Following the completion of the transaction, the insider now directly owns 15,000 shares in the company, valued at approximately $274,200. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, General Counsel Paul T. Quinlan sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $23.58, for a total transaction of $117,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Charles Mcwherter sold 11,342 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $18.28, for a total value of $207,331.76. Following the completion of the sale, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately $274,200. The disclosure for this sale can be found here. Insiders have sold 164,439 shares of company stock worth $3,470,441 over the last quarter. 7.00% of the stock is currently owned by insiders.

Institutional Trading of CymaBay Therapeutics

Several institutional investors have recently made changes to their positions in the company. Harvest Fund Management Co. Ltd acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at approximately $26,000. AJOVista LLC acquired a new position in CymaBay Therapeutics in the 4th quarter valued at about $42,000. China Universal Asset Management Co. Ltd. increased its stake in CymaBay Therapeutics by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,516 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,238 shares during the period. Wetzel Investment Advisors Inc. acquired a new stake in shares of CymaBay Therapeutics during the fourth quarter worth about $71,000. Finally, Great West Life Assurance Co. Can purchased a new position in shares of CymaBay Therapeutics in the first quarter valued at approximately $40,000. Hedge funds and other institutional investors own 95.03% of the company’s stock.

CymaBay Therapeutics Company Profile

(Get Free Report)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).

Further Reading

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.